Columbus McKinnon Corporation — Form 10-Q Summary
Business context and reporting period
Columbus McKinnon designs, manufactures, and markets intelligent motion solutions, including hoists, crane components, precision conveyors, actuators, rigging tools, workstations, and digital power and motion-control systems. The filing covers the fiscal second quarter and six months ended September 30, 2022; the comparable period ended September 30, 2021. Results are unaudited and are not necessarily indicative of the full fiscal year ending March 31, 2023.
Approximately 60% of second-quarter sales and 62% of six-month sales were to U.S. customers. The company completed its Garvey acquisition in December 2021, following the Dorner acquisition in April 2021.
Financial performance and liquidity
| Metric | Three months ended September 30, 2022 | Three months ended September 30, 2021 | Six months ended September 30, 2022 | Six months ended September 30, 2021 |
|---|---|---|---|---|
| Net sales | $231.7 million | $223.6 million | $452.0 million | $437.1 million |
| Gross profit | $86.3 million | $81.1 million | $168.8 million | $155.2 million |
| Gross margin | 37.2% | 36.3% | 37.4% | 35.5% |
| Income from operations | $27.4 million | $23.7 million | $50.2 million | $34.4 million |
| Net income | $14.1 million | $15.2 million | $22.5 million | $7.9 million |
| Diluted EPS | $0.49 | $0.53 | $0.78 | $0.28 |
Second-quarter sales increased 3.6%, while six-month sales increased 3.4%. Management attributed the increases primarily to pricing and acquired Garvey revenue, partly offset by lower volume and unfavorable foreign-currency translation. Operating margin was approximately 11.8% in the quarter and 11.1% for the six months, based on reported operating income and sales.
Six-month net income benefited from the absence of prior-year debt-refinancing costs of $14.8 million and lower acquisition and integration expenses. Second-quarter net income declined despite higher operating income because interest expense, foreign-exchange losses, investment losses, and other expense increased.
- Six-month selling expense rose to $51.8 million from $47.6 million, while research and development expense rose to $10.6 million from $7.4 million.
- Six-month interest and debt expense increased to $13.0 million from $10.4 million, reflecting higher variable interest rates and Garvey-related borrowings.
- The six-month effective tax rate was 38%, versus 16% in the prior-year period, due primarily to tax-assessment settlements, a U.S. state valuation allowance, and jurisdictional mix. Management estimated a fiscal 2023 effective tax rate of approximately 29% to 31%.
- The company declared a quarterly dividend of $0.07 per share.
Cash flow, debt, and balance sheet
- Cash, cash equivalents, and restricted cash were $89.1 million at September 30, 2022, down $26.5 million from March 31, 2022. Cash and cash equivalents alone were $88.9 million.
- Six-month operating cash flow was $6.1 million, down from $17.9 million. Inventory increased by $30.8 million, largely reflecting supply-chain constraints, while accounts payable and accrued liabilities declined.
- Capital expenditures were $5.3 million for the six months. Fiscal 2023 capital expenditures were expected to range from $12 million to $15 million.
- Six-month investing cash use was $7.0 million, including capital expenditures and a $1.6 million final Garvey working-capital adjustment.
- Six-month financing cash use was $24.4 million, including $20.3 million of debt repayment and $4.0 million of dividends.
- The Term Loan B principal balance was $482.6 million, including $75.0 million borrowed through the Garvey-related accordion feature. The balance-sheet carrying amount of term loan and finance lease obligations was $450.8 million, plus $40.6 million of current maturities and finance lease obligations.
- The company had no revolver borrowings and $16.0 million of outstanding letters of credit against its $100 million revolving facility. Management planned approximately $40 million of total principal repayments over the following 12 months, compared with $5.3 million of scheduled principal payments before any required excess-cash-flow payment.
- Management stated that cash on hand, operating cash flow, and borrowing capacity should fund operations, debt obligations, and capital expenditures for at least the next 12 months, subject to execution of the business plan and effective working-capital management.
Material changes, outlook, and unusual items
- Pricing contributed $11.0 million of second-quarter sales growth and $20.6 million of six-month sales growth. Garvey contributed $9.0 million and $17.5 million, respectively. Foreign-currency translation reduced sales by $11.0 million in the quarter and $18.0 million for six months.
- Gross-margin expansion reflected pricing net of material inflation, Garvey, favorable product mix, productivity, and the absence of certain prior-year costs. These benefits were partly offset by tariffs, productivity pressure, and foreign-currency translation.
- Management reported higher raw-material, freight, and logistics costs and continued availability issues for selected materials and components. Price increases had generally recovered these costs to date, but the company stated it might not be able to pass through future increases.
- The company is investing in new products and its Columbus McKinnon Business System, with initiatives focused on business simplification, delivery performance, warranty costs, productivity, and operating margins.
- No goodwill impairment indicators were identified during the quarter. Goodwill totaled $627.9 million at September 30, 2022, and future impairment could result from lower cash-flow forecasts, lower margins, higher discount rates, or other valuation changes.
- Remaining unsatisfied performance obligations were approximately $10.7 million, of which approximately 37% was expected to be recognized over the following 12 months.
Risks, contingencies, and controls
- Key risks include global economic conditions, industrial demand, supply-chain disruption, raw-material and freight inflation, foreign-exchange movements, rising interest rates, acquisition integration, customer and supplier conditions, and competitive pressures.
- Asbestos-related aggregate liability was estimated at $5.8 million to $10.6 million net of insurance recoveries, with approximately $7.7 million recorded as probable and estimable. Management expected approximately $2.4 million of asbestos payments over the next 12 months.
- Recorded product-liability reserves were approximately $5.4 million, and other asbestos-related claims involving a former business were estimated at approximately $0.5 million.
- Magnetek remains involved in Italian tax proceedings and disputes involving Monsanto and insurance coverage. The company stated that it does not expect a liability from the Italian assessments and cannot reasonably estimate a potential loss related to the Monsanto matter.
- Environmental liabilities totaled approximately $0.8 million. Management stated that known environmental matters were not expected to have a material effect on results, financial condition, or cash flows.
- Management concluded that disclosure controls and procedures were effective as of September 30, 2022. No material changes in reported risk factors or market risks were identified compared with the 2022 Form 10-K.
Important facts for investors to verify
- Whether pricing continues to offset raw-material, freight, tariff, and logistics inflation without weakening demand or margins.
- Inventory reduction, working-capital conversion, and the resulting improvement or deterioration in operating cash flow.
- Progress toward the planned approximately $40 million of debt repayment and sensitivity to higher variable interest rates.
- Garvey and Dorner integration performance, including revenue growth, synergies, margins, and acquisition-related costs.
- Foreign-currency effects, particularly the impact of a stronger U.S. dollar on sales, gross profit, and accumulated other comprehensive loss.
- Developments in asbestos, product-liability, Italian tax, Monsanto, and environmental matters, including potential cash payments beyond recorded reserves.
- Actual fiscal 2023 tax rates and capital expenditures relative to management’s 29%–31% tax-rate estimate and $12 million–$15 million capital-expenditure range.